This effect on anemia is distinct from erythropoiesis-stimulating agents, which are less effective in patients with iron deficiency, and underscore the concept that SGLT2 inhibitors improve iron availability but may not worsen iron deficiency [14]. This evidence concerns the gene SLC5A2 and anemia.